ProfileGDS5678 / 1436392_s_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 72% 70% 71% 72% 69% 71% 74% 79% 81% 76% 72% 75% 71% 72% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 14.5209572
GSM967853U87-EV human glioblastoma xenograft - Control 24.3372770
GSM967854U87-EV human glioblastoma xenograft - Control 34.4810271
GSM967855U87-EV human glioblastoma xenograft - Control 44.674672
GSM967856U87-EV human glioblastoma xenograft - Control 54.2537969
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 14.4447771
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 24.7928274
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 35.5296679
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 45.8256281
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 15.1925176
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 24.5467972
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 34.9876575
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 44.4678171
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 54.6066572